Propamidine

Summary

Propamidine (CHEMBL23013) is a phase-3 clinical-stage small-molecule antimicrobial agent (ATC S01AX15); indicated across 2 conditions including acanthamoeba keratitis and eye infectious disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: S01AX15 (+1 more)
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 312.37 Da · C17H20N4O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL23013
Name	Propamidine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	64949
ChEBI	CHEBI:87462
ATC	S01AX15, D08AC03
Molecular formula	C17H20N4O2
Molecular weight	312.37
InChIKey	WTFXJFJYEJZMFO-UHFFFAOYSA-N

SMILES: C1=CC(=CC=C1C(=N)N)OCCCOC2=CC=C(C=C2)C(=N)N

IUPAC name: 4-[3-(4-carbamimidoylphenoxy)propoxy]benzenecarboximidamide

ChEBI definition: A polyether that is the bis(4-guanidinophenyl) ether of propane-1,3-diol. Used (as its isethionate salt) for the treatment of minor eye or eyelid infections, such as conjunctivitis and blepharitis.

Pharmacological roles (ChEBI): antimicrobial agent, antiseptic drug.

Also known as: M&B 782 FREE BASE, M&B-782 FREE BASE, Propamidina, Propamidine, SID144206602, propamidine, PROPAMIDINE

Parent form; salt/anhydrous children: CHEMBL3216426

Patent coverage: 1,348 distinct patent families (5,100 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Transmembrane protease serine 2, Glutamate NMDA receptor, Acrosin.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P08001	5.46	Ki	3500	nM	CHEMBL_ACT_14619945
P35439	5.26	IC50	5540	nM	CHEMBL_ACT_15653046
TMPRSS2	5.05	IC50	9000	nM	CHEMBL_ACT_25068124

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Acanthamoeba keratitis	3	MONDO:0005629	EFO:0007126
eye infectious disorder	3	MONDO:0043885	EFO:1001888

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03274895	PHASE3	COMPLETED	Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).